New Clinical Data Supports NeutraSal® in the Treatment of Oral Mucositis

Share Article

Invado Pharmaceuticals announced the acceptance of two clinical excerpts for their lead product NeutraSal, a product indicated for the treatment of oral mucositis. Invado also announced the initiation of several phase IV clinical trials involving NeutraSal®. For more information, go to http://www.neutrasal.com

Invado Pharmaceuticals announced the acceptance of two clinical excerpts for their lead product NeuInvado Pharmaceuticals announced the acceptance of two clinical excerpts for their lead product NeutraSal, a product indicated for the treatment of oral mucositis. Michelle Thaden, RN at the Mobile Infirmary in Alabama will present at the 36th Annual ONS Congress a case study showing successful resolution of severe mucositis in a nasopharyngeal carcinoma pediatric patient that presented painful mucositis after failing on prior amifostine treatment. The patient was debilitated with “pus-filled” mouth ulcers, xerostomia and dysgeusia. The patient reported his mouth cleared and the ability to eat and talk resumed in one day. “We were shocked at how quickly the patient responded to NeutraSal®,” said Ms. Thaden. She continued, “It’s a great little product!”

Another case study completed by Ather Siddiqi, MD at the South Texas Oncology Center in San Antonio Texas demonstrated the prevention of mucositis by NeutraSal® in a patients undergoing chemoradiation for advanced head and neck cancer of the tongue.    Historically, the incidence of oral mucositis in patients undergoing combination of chemotherapy and radiation is nearly 100%. The patient was prophylactically treated with NeutraSal® and successfully completed his full course of radiation treatment and chemotherapy without the use of a feeding tube, without the need of parental morphine, and the patient did not miss any treatments.

Invado also announced the initiation of several phase IV clinical trials involving NeutraSal®.

Kishore Dass, MD of South Florida Radiation Oncology is the principal investigator of a multi-site registry collection in the treatment of oral mucositis in patients undergoing high dose chemotherapy and radiation therapy.

John Fritz, MD, Hudson Primary Care Professionals, Jersey City, New Jersey has initiated a small pilot study of the use of NeutraSal® in relieving medication-induced xerostomia (dry mouth).

David Shepherd, DDS, Birmingham, Alabama has begun a large scale study on the use of NeutraSal® in the reversal of dental caries in patients with chronic xerostomia including patients who had undergone prior radiation therapy of the head and neck.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Edward Kobus
Visit website